Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Streptococcus Salivarius Evol12® in Improving Quality of Life in Locally Advanced Head and Neck Cancer Treated With Radio(Chemo)Therapy: SMILE (SMILE)

18. november 2026 opdateret af: Aurora Mirabile, IRCCS San Raffaele

Streptococcus Salivarius Evol12® in Improving Quality of Life In Locally Advanced Head and Neck Cancer Treated With radiochEmotherapy: SMILE, a Monocentric National Randomized Double Blind Interventional Study

The clinical study will involve the use of a dietary supplement based on the oral probiotic strain Streptococcus salivarius Evol12® in patients with head and neck cancer undergoing radiochemotherapy, with the aim of improving their quality of life. The hypothesis is that, as already outlined in scientific literature, modifying the oral microbiota through the use of the commensal S. salivarius, increasing its concentration and reducing the main pathogens in the oral cavity, may protect these patients and reduce the impact on their quality of life . A discovery of this kind would allow patients with head and neck cancer to be treated not only with standard therapy but also with treatments designed to modify the oral microbiota, which is not currently taken into consideration, in order to improve these patients' quality of life and compliance with treatment. Compared to the S. salivarius K12 strain, the S. salivarius eK12 (Evol12®) strain has a genome that is entirely similar to K12, but with a hypothetically greater antibacterial activity due to the presence of two specific genetic differences which allow for increased release of a bacteriocin: the salivabactin. Streptococcus salivarius eK12 (Evol12®) has undergone mutagenesis, acute toxicity, and subchronic toxicity studies in animals, conducted according to OECD guidelines by a GLPcertified laboratory, confirming its safety of use and absence of toxicity (In vitro and In vivo safety evaluation of Streptococcus salivarius eK12, a genetically modified dietary probiotic derived from the oral probiotic S. salivarius K12). In addition, a randomized, double-blind, placebo-controlled clinical trial conducted in healthy adults has been published, demonstrating its complete safety of use even at high dosages.

Studieoversigt

Status

Ikke rekrutterer endnu

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

170

Fase

  • Ikke anvendelig

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år og ældre (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  1. Participants are willing and able to give informed consent for participation in the study.
  2. Aged >=18 years
  3. Patients diagnosed with non-metastatic head and neck malignant tumors, with an Eastern Cooperative Oncology Group performance status of ≤2, planning to receive definitive RT or postoperative adjuvant RT concomitant to cisplatin.
  4. Patient affected by squamocellular carcinoma of oral cavity, larynx, hypopharynx, oropharynx and undifferentiated or squamocellular carcinoma of nasopharynx.
  5. Patients eligible for to receive definitive RT or postoperative adjuvant RT concomitant to cisplatin.

Exclusion Criteria:

  1. Patients with a history of allergy to probiotics or severe allergic constitution
  2. Use of antibiotics/antifungal drugs within 1 month or antimicrobial mouthwash within 1 week before the study
  3. Poor oral hygiene and/or severe periodontal diseases (CTCAE 5.0 Grading >/=2)
  4. Any previous RT to the head and neck region
  5. Those deemed unsuitable for the study by the investigators (concomitant with any other severe diseases)
  6. Allergies: history of known allergies to probiotics or to product excipients.
  7. Recent antimicrobial therapies: use of systemic antibiotics or antifungals within 1 month, or antimicrobial mouthwashes within 1 week.
  8. Oral cavity conditions: severely compromised oral hygiene or severe periodontal disease.
  9. Previous radiotherapy: any prior radiotherapy (RT) to the head and neck region.
  10. Severe comorbidities: severe concomitant diseases that make the patient unsuitable according to clinical judgment.
  11. Pregnancy and breastfeeding
  12. Contraindication related to probiotic composition
  13. Primary sites different from the ones described in inclusion criteria
  14. Patient unfit to cisplatin
  15. Immunocompromised Patients

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Støttende pleje
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Dobbelt

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Placebo komparator: placebo group

The placebo lozenges will be identical in appearance, taste, and composition, but will contain only excipients (sugar and starch), without any active bacteria.

Participants will be instructed to slowly dissolve one lozenge in the mouth three times daily (morning, afternoon, and evening) throughout the entire radiotherapy (RT) period. Patients will also be advised to avoid eating, drinking, or performing oral hygiene procedures for at least one hour after administration

Eksperimentel: group treated with probiotic: Streptococcus salivarius Evol12®

The investigational product (Bactoblis® Evol, containing the probiotic strain Streptococcus salivarius Evol12®) will be provided in the form of oral lozenges, each containing ≥ 1 × 10⁹ colony-forming units (CFU) of viable S. salivarius Evol12® cells as the active ingredient.

Participants will be instructed to slowly dissolve one lozenge in the mouth three times daily (morning, afternoon, and evening) throughout the entire radiotherapy (RT) period.

Participants will be instructed to slowly dissolve one lozenge in the mouth three times daily (morning, afternoon, and evening) throughout the entire radiotherapy (RT) period. Patients will also be advised to avoid eating, drinking, or performing oral hygiene procedures for at least one hour after administration, in order to ensure optimal mucosal contact and promote probiotic colonization.

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
EORTC QLQ-H&N35 score
Tidsramme: It will be assessed before treatment, 3 weeks, 8 weeks and subsequently for up to 8 weeks.

Change in quality of life assessed using the EORTC QLQ-H&N35 scale before treatment, 3 weeks, at the end of treatment (8 weeks) and thereafter for up to 8 weeks.

It will be assessed before treatment, 3 weeks, 8 weeks and subsequently for up to 8 weeks.

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
days
Tidsramme: It will be assessed before treatment, 3 weeks, 8 weeks and subsequently for up to 8 weeks.

Time to onset (days) of WHO grade ≥2 and ≥3.

It will be assessed before treatment, 3 weeks, 8 weeks and subsequently for up to 8 weeks.
days
Tidsramme: It will be assessed before treatment, 3 weeks, 8 weeks and subsequently for up to 8 weeks.

Duration (days) of WHO grade ≥2 and ≥3.

It will be assessed before treatment, 3 weeks, 8 weeks and subsequently for up to 8 weeks.
Percentage
Tidsramme: It will be assessed before treatment, 3 weeks, 8 weeks and subsequently for up to 8 weeks.

Rate of RT/chemotherapy interruptions, dose reduction or delay due to toxicity.

It will be assessed before treatment, 3 weeks, 8 weeks and subsequently for up to 8 weeks.
Numeric Rating Scale (NRS)
Tidsramme: It will be assessed before treatment, 3 weeks, 8 weeks and subsequently for up to 8 weeks.

Change in Pain Scores Over Time, assessed using the Numeric Rating Scale (NRS; 0-10), where 0 indicates no pain and 10 indicates the worst pain imaginable. Higher scores indicate greater pain intensity and a worse outcome.

It will be assessed before treatment, 3 weeks, 8 weeks and subsequently for up to 8 weeks.
Percentage
Tidsramme: It will be assessed before treatment, 3 weeks, 8 weeks and subsequently for up to 8 weeks.

Percentage of patients requiring enteral or parenteral nutritional support according to the percentage of weight loss (≥5% o ≥10%).

It will be assessed before treatment, 3 weeks, 8 weeks and subsequently for up to 8 weeks.
days
Tidsramme: It will be assessed before treatment, 3 weeks, 8 weeks and subsequently for up to 8 weeks.

duration of RT/chemotherapy interruptions, dose reduction or delay due to toxicity.

It will be assessed before treatment, 3 weeks, 8 weeks and subsequently for up to 8 weeks.

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Anslået)

1. januar 2027

Primær færdiggørelse (Anslået)

1. januar 2027

Studieafslutning (Anslået)

1. december 2028

Datoer for studieregistrering

Først indsendt

4. november 2026

Først indsendt, der opfyldte QC-kriterier

18. november 2026

Først opslået (Faktiske)

20. november 2026

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

20. november 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

18. november 2026

Sidst verificeret

1. november 2026

Mere information

Begreber relateret til denne undersøgelse

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

INGEN

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner